Sonntag, 7. März 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE

KarMMa-3 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Rekrutierend

NCT-Nummer:
NCT03651128

Studienbeginn:
Oktober 2018

Letztes Update:
11.08.2020

Wirkstoff:
bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab

Indikation (Clinical Trials):
Multiple Myeloma, Neoplasms, Plasma Cell

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Celgene

Collaborator:
-

Studienleiter

Steven Novick, MD
Study Director
Celgene

Kontakt

Associate Director Clinical Trial Disclosure
Kontakt:
Phone: 1-888-260-1599
E-Mail: clinicaltrialdisclosure@celgene.com
» Kontaktdaten anzeigen

Studienlocations (3 von 49)

Medizinische Universitaetsklinik Heidelberg
69120 Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
University Hospital of Cologne
50937 Köln
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Universitaetsklinikum Wuerzburg
97080 Würzburg
(Bayern)
GermanyRekrutierend» Google-Maps
University of Alabama Birmingham
10016 Birmingham
United StatesRekrutierend» Google-Maps
Mayo Clinic Arizona
85259 Scottsdale
United StatesRekrutierend» Google-Maps
UCLA Medical Centre-Santa Monica Hematology and Oncology
90095 Los Angeles
United StatesRekrutierend» Google-Maps
University of Colorado Anschutz Cancer Pavilion
80045 Aurora
United StatesRekrutierend» Google-Maps
Mayo Clinic - Jacksonville
32224 Jacksonville
United StatesRekrutierend» Google-Maps
Emory University Hospital
30322 Atlanta
United StatesRekrutierend» Google-Maps
Blood and Marrow Transplant Group of Georgia
30342 Atlanta
United StatesRekrutierend» Google-Maps
Northwestern University Feinberg School of Medicine
60611 Chicago
United StatesRekrutierend» Google-Maps
Indiana University Health Melvin and Bren Simon Cancer Center
46202-528 Indianapolis
United StatesRekrutierend» Google-Maps
The University of Kansas Hospital
66205-2003 Westwood
United StatesRekrutierend» Google-Maps
Greenebaum University of Maryland
21201-1595 Baltimore
United StatesRekrutierend» Google-Maps
Dana Farber Cancer Institute (DFCI)
02215 Boston
United StatesRekrutierend» Google-Maps
University of Michigan Comprehensive Cancer Center
48109-5936 Ann Arbor
United StatesRekrutierend» Google-Maps
Mayo Clinic - Rochester
55905 Rochester
United StatesRekrutierend» Google-Maps
Washington University School of Medicine, Siteman Cancer Center
63110 Saint Louis
United StatesRekrutierend» Google-Maps
Hackensack University Medical Center
07601 Hackensack
United StatesRekrutierend» Google-Maps
Mount Sinai Medical Center
10029 New York
United StatesRekrutierend» Google-Maps
New York Presbyterian Hospital Weil Cornell Medical College
10065 New York
United StatesRekrutierend» Google-Maps
Duke Clinical Research Institute Duke University School of Medicine
27705 Durham
United StatesRekrutierend» Google-Maps
Thomas Jefferson University
19107 Philadelphia
United StatesRekrutierend» Google-Maps
Fox Chase Cancer Center
19111 Philadelphia
United StatesRekrutierend» Google-Maps
University of Pittsburgh Medical Center - William M. Cooper Ambulatory Care Pavilion
15232 Pittsburgh
United StatesRekrutierend» Google-Maps
Sarah Cannon Research Institute Center for Blood
37203: Nashville
United StatesRekrutierend» Google-Maps
Baylor University Medical Center at Dallas
75246 Dallas
United StatesRekrutierend» Google-Maps
MD Anderson Cancer center
77030 Houston
United StatesRekrutierend» Google-Maps
University of Utah Huntsman Cancer Center
84112 Salt Lake City
United StatesRekrutierend» Google-Maps
Swedish Cancer Institute
98104 Seattle
United StatesRekrutierend» Google-Maps
University of Wisconsin Carbone Cancer Center
53792 Madison
United StatesRekrutierend» Google-Maps
Princess Margaret Cancer Centre
M5G 2M9 Toronto
CanadaRekrutierend» Google-Maps
Centre Hospitalier Univ De Nantes Hotel-Dieu
44093 Nantes
FranceRekrutierend» Google-Maps
Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi - Istituto di Ematolog
40138 Bologna
ItalyRekrutierend» Google-Maps
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
113-8677 Bunkyo-ku
JapanRekrutierend» Google-Maps
Tokai University Hospital
259-1193 Isehara, Kanagawa
JapanRekrutierend» Google-Maps
Japan Red Cross Medical Center
150-8935 Shibuya-ku
JapanRekrutierend» Google-Maps
Erasmus Medical Center
3015 CN Rotterdam
NetherlandsRekrutierend» Google-Maps
Oslo universitetssykehus, Rikshospitalet
N-0027 Oslo Universitetssykehus, Rikshospitalet
NorwayRekrutierend» Google-Maps
Clinica Universidad de Navarra
31008 Pamplona
SpainRekrutierend» Google-Maps
Hospital Universitario de Salamanca
37007 Salamanca
SpainRekrutierend» Google-Maps
Karolinska Universitetssjukhuset - Huddinge
SE-141 86 Stockholm
SwedenRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).

The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.

Ein-/Ausschlusskriterien

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).

2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.

3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements within this protocol and for a subject randomized to Treatment Arm A, subject agrees to continued follow-up for up to 15 years as mandated by the regulatory guidelines for gene therapy trials.

4. Subject has documented diagnosis of MM and measurable disease, defined as:

- M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP ≥ 0.5 g/dL or uPEP ≥ 200 mg/24 hours and/or

- Light chain MM without measurable disease in the serum or urine: Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio

5. Subject has received at least 2 but no greater than 4 prior MM regimens.

6. Subject has received prior treatment with DARA, a proteasome inhibitor- and an immunomodulatory compound-containing regimen for at least 2 consecutive cycles.

7. Subject must be refractory to the last treatment regimen. Refractory is defined as documented progressive disease during or within 60 days (measured from the last dose of any drug within the regimen) of completing treatment with the last anti-myeloma regimen before study entry.

8. Subject achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen.

9. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

10. Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 peripheral neuropathy.

11. Adequate vascular access for leukapheresis

12. Females of childbearing potential (FCBP) must:

a. Have negative pregnancy test(s) as verified by the Investigator. This applies even if the subject practices true abstinence from heterosexual contact.

b. Either practice true abstinence from heterosexual contact or agree to use, and be able to comply with, effective measures of contraception without interruption.

c. Agree to abstain from breastfeeding during study participation. d. Refrain from tissue donation including egg cell donation or any other tissue/blood/organ donations.

13. Male subjects must:

a. Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, even if he has undergone a successful vasectomy.

b. Refrain from tissue donation including sperm or any other tissue/blood/organ donations.

14. Only subjects that would be considered for any of the 5 proposed standard regimens (DPd, DVd, IRd, Kd, or EPd), as judged by the investigator, should be included in the study.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

1. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.

3. Subject has any condition that confounds the ability to interpret data from the study.

4. Subject has nonsecretory multiple myeloma (MM).

5. Subject has any of the following laboratory abnormalities:

a. Absolute neutrophil count (ANC) < 1,000/μL b. Platelet count: < 75,000/μL in subjects in whom < 50% of bone marrow nucleated cells are plasma cells and platelet count < 50,000/μL in subjects in whom ≥ 50% of bone marrow nucleated cells are plasma cells (it is not permissible to transfuse a subject to reach this level) c. Hemoglobin < 8 g/dL (< 4.9 mmol/L) (it is not permissible to transfuse a subject to reach this level) d. Serum creatinine clearance (CrCl) < 45 mL/min e. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L) f. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN) g. Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome h. International normalized ratio (INR) or activated partial thromboplastin time (aPTT) > 1.5 × ULN, or history of Grade ≥ 2 hemorrhage within 30 days, or subject requires ongoing treatment with chronic, therapeutic dosing of anticoagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors)

6. Subject has inadequate pulmonary function defined as oxygen saturation (SaO2) < 92% on room air.

7. Subject has prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years • Basal cell carcinoma of the skin

• Squamous cell carcinoma of the skin

- Carcinoma in situ of the cervix

- Carcinoma in situ of the breast

- Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system) or prostate cancer that can be treated with curative intent

8. Subject has active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome or amyloidosis.

9. Subject with known central nervous system (CNS) involvement with myeloma.

10. Subject has clinical evidence of pulmonary leukostasis and disseminated intravascular coagulation.

11. Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) 50% of predicted normal.

12. Subject has a history or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, subarachnoid hemorrhage or other CNS bleed, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.

13. Subject was treated with DARA in combination with POM with or without dex (DP±d) as part of their most recent anti-myeloma treatment regimen, cannot receive DPd as bridging therapy but may receive DVd, IRd, Kd or EPdas bridging as per Investigator's discretion if randomized to Treatment Arm A.

14. Subject was treated with DP±d as part of their most recent anti-myeloma treatment regimen, cannot receive DPd if randomized to Treatment Arm B but may receive DVd, IRd, Kd, or EPd as per Investigator's discretion.

15. Subject was treated with DARA in combination with BTZ with or without dexamethasone (DV±d) as part of their most recent anti-myeloma treatment regimen, cannot receive DVd as bridging therapy but may receive DPd, IRd, Kd, or EPd as bridging as per Investigator's discretion if randomized to Treatment Arm A.

16. Subject was treated with DV±d as part of their most recent anti-myeloma treatment regimen, cannot receive DVd if randomized to Treatment Arm B but may receive DPd, IRd, Kd, or EPd as per Investigator's discretion.

17. Subject was treated with IXA in combination with LEN with or without dexamethasone (IR±d) as part of their most recent anti-myeloma treatment regimen, cannot receive IRd as bridging therapy but may receive DPd, DVd, Kd, or EPd as bridging as per Investigator's discretion if randomized to Treatment Arm A.

18. Subject was treated with IR±d as part of their most recent anti-myeloma treatment regimen, cannot receive IRd if randomized to Treatment Arm B but may receive DPd, DVd, Kd, or EPd as per Investigator's discretion.

19. Previous history of an allogeneic hematopoietic stem cell transplantation, treatment with any gene therapy-based therapeutic for cancer, investigational cellular therapy for cancer or BCMA targeted therapy.

20. Subject has received autologous stem cell transplantation (ASCT) within 12 weeks prior to randomization.

21. Subject has received any of the following within the last 14 days prior to randomization:

a. Plasmapheresis b. Major surgery (as defined by the Investigator) c. Radiation therapy other than local therapy for myeloma-associated bone lesions d. Use of any investigational agents and systemic anti-myeloma drug therapy

22. Echocardiogram (ECHO) or multigated acquisition (MUGA) with left ventricular ejection fraction (LVEF) < 45%.

23. Ongoing treatment with chronic immunosuppressants (eg, cyclosporine or systemic steroids at any dose). Intermittent topical, inhaled or intranasal corticosteroids are allowed.

24. Subject is positive for human immunodeficiency virus (HIV-1 and HIV-2), chronic or active hepatitis B or active hepatitis A or C.

25. Subject has uncontrolled systemic fungal, bacterial, viral or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antimicrobial treatment) or requiring IV antimicrobials for management.

26. Subject has a history of class III or IV congestive heart failure (CHF) or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to randomization.

27. Hypersensitivity to DARA, thalidomide, lenalidomide, POM, BTZ, IXA, CFZ, ELO or dexamathasone. This includes rash ≥ Grade 3 during prior thalidomide, POM or lenalidomide therapy.

28. Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine, and/or tocilizumab or hypersensitivity to the excipients contained in the formulation of DARA, POM, LEN, IXA, BTZ, CFZ, ELO or dexamethasone.

29. Subject is a female who is pregnant, nursing, or breastfeeding

30. For a subject randomized to Treatment Arm B and will be on a POM- or LEN-containing regimen; unable or unwilling to undergo protocol required thromboembolism prophylaxis.

28 Subject is intolerant to bortezomib, or has acute diffuse infiltrative pulmonary and pericardial disease, subject cannot receive DVd as bridging therapy if randomized to Treatment Arm A or cannot receive DVd if randomized to Treatment Arm B.

31. Subject was treated with K±d as part of their most recent anti-myeloma treatment regimen, cannot receive Kd if randomized to Treatment Arm B but may receive DPd, DVd, IRd or EPd as per Investigator's discretion.

32. Subject was treated with EP±d as part of their most recent anti-myeloma treatment regimen, cannot receive EPd if randomized to Treatment Arm B but may receive DPd, DVd, Kd or IRd as per Investigator's discretion.

Studien-Rationale

Primary outcome:

1. Progression-free Survival (PFS) (Time Frame - Minimum of 5 years from randomization):
Time from randomization to the first documentation of progressive disease based on the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma assessed by an independent response committee (IRC) or death due to any cause, whichever occurs first.



Secondary outcome:

1. Overall Survival (OS) (Time Frame - Minimum of 5 years from randomization):
Time from randomization to time of death due to any cause

2. Event-free Survival (EFS) (Time Frame - Minimum of 5 years from randomization):
Time from randomization to the first documentation of progressive disease, first day when subject receives another anti-myeloma treatment or death due to any cause, whichever occurs first

3. Overall Response Rate (ORR) (Time Frame - Minimum of 5 years from randomization):
Percentage of subjects who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by an IRC

4. Minimal Residual Disease (MRD) (Time Frame - Minimum of 5 years from randomization):
Percentage of MRD evaluable subjects that are MRD negative (defined at a minimum of 1 in 10^5 nucleated cells) using flow cytometry (EuroFlow) and next generation sequencing (NGS)

5. Complete Response (CR) Rate (Time Frame - Minimum of 5 years from randomization):
Percentage of subjects who achieved CR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by an IRC

6. Duration of Response (DOR) (Time Frame - Minimum of 5 years from randomization):
Time from first documentation of response (PR or better) to first documentation of disease progression or death from any cause, whichever occurs first

7. Time to Response (TTR) (Time Frame - Minimum of 5 years from randomization):
TTR is calculated as the time from randomization to the initial documented response (PR or better) based on IMWG guideline for responders

8. Adverse Events (AEs) (Time Frame - Minimum of 5 years from randomization):
Number of participants with adverse events

9. Pharmacokinetics- Cmax (Time Frame - Minimum 5 years after bb2121 infusion):
Maximum peak in bb2121 chimeric antigen receptor (CAR) T cells

10. Pharmacokinetics- tmax (Time Frame - Minimum 5 years after bb2121 infusion):
Time to peak of bb2121 CAR T cells

11. Pharmacokinetics- AUC (Time Frame - Minimum 5 years after bb2121 infusion):
Area under the curve of CAR T cells

12. Pharmacokinetics- t-last (Time Frame - Minimum 5 years after bb2121 infusion):
Time to last measurable CAR T cells

13. Pharmacokinetics- AUC0-28days (Time Frame - Minimum 5 years after bb2121 infusion):
Area under the curve of CAR T cells from time zero to Day 28

14. Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30) (Time Frame - Minimum of 5 years from randomization):
Questionnaire will be used as a measure of health-related quality of life

15. Subject-reported outcomes as measured by EuroQoL Group European Quality of Life-5 Dimensions health state classifier to 5 Levels (EQ-5D-5L) Health Questionnaire (Time Frame - Minimum of 5 years from randomization):
Is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal

16. Subject-reported outcomes as measured by European Quality of Life Multiple Myeloma Module (EORTC-QLQ-MY20) (Time Frame - Minimum of 5 years from randomization):
Is a 20-item myeloma module intended for use among patients varying in disease stage and treatment modality

17. Time to next antimyeloma treatment (Time Frame - Minimum of 5 years from randomization):
Time from randomization to first day when subject receives another anti-myeloma treatment

18. Progression-free survival after next line therapy (PFS2) (Time Frame - Minimum of 5 years from randomization):
Time from randomization to second objective disease progression or death from any cause, whichever is first

Studien-Arme

  • Experimental: Arm A - Administration of bb2121
    bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
  • Experimental: Arm B- standard regimens as per Investigator's discretion
    The participants will receive one of following regimens dependent on the subject's most recent anti-myeloma treatment regimen: Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd) OR DARA in combination with bortezomib (BTZ) and low-dose dex (DVd) OR Ixazomib (IXA) in combination with lenalidomide (LEN) and low-dose dex (IRd) OR Carfilzomib (CFZ) in combination with low-dose dexamethasone (Kd) OR Elotuzumab (ELO) in combination with POM and low-dose dexamethasone (EPd)

Geprüfte Regime

  • bb2121:
    bb2121
  • Daratumumab:
    Daratumumab
  • Pomalidomide:
    Pomalidomide
  • Dexamethasone:
    Dexamethasone
  • Bortezomib:
    Bortezomib
  • Ixazomib:
    Ixazomib
  • Lenalidomide:
    Lenalidomide
  • Carfilzomib:
    Carfilzomib
  • Elotuzumab:
    Elotuzumab

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Was Krebspatienten in der kalten Jahreszeit beachten sollten

Was Krebspatienten in der kalten Jahreszeit beachten sollten
© Rido - stock.adobe.com

Außen kalt, innen überheizt, dazu Glatteis, Schnee und trübes Licht – der Winter ist für Krebspatienten keine leichte Zeit. Aufgrund der geschwächten Immunabwehr und den damit einhergehenden gesundheitlichen Beeinträchtigungen sind besondere Vorsichtsmaßnahmen zu beachten. Im Monatsthema Dezember gibt das ONKO-Internetportal hilfreiche Tipps, wie Krebspatienten gut und sicher durch die kalten Monate kommen.

Primäre Studienendpunkte: Gesamtüberleben oder progressionsfreies Überleben - gibt es einen Goldstandard?

Anerkanntes Ziel einer Therapie von Krebspatienten ist die Verbesserung des Überlebens und der Lebensqualität. Historisch gesehen gilt die Gesamtüberlebenszeit (OS = overall survival) als der wichtigste primäre klinische Endpunkt einer Studie. Doch das Gesamtüberleben als primärer Studienendpunkt unterliegt nicht zuletzt aufgrund der Fortschritte, die in letzten Jahren in der Krebstherapie erzielt wurden, gewissen Einschränkungen. So können...

Biopharmazeutika sind den meisten Deutschen unbekannt

Biopharmazeutika sind den meisten Deutschen unbekannt
© Darren Baker / Fotolia.com

Naturheilmittel oder neuer Trend der Bio-Welle? 94 Prozent der Deutschen können mit dem Begriff Biopharmazeutika nichts anfangen (1). Oftmals werden hinter dem Begriff Naturheilmittel vermutet. Dabei handelt es sich um Arzneimittel, die biotechnisch hergestellt oder aus gentechnisch veränderten Organismen gewonnen werden und mit dem Ziel der Bekämpfung einer Krankheit in die Vorgänge des Körpers eingreifen. Insulin ist ein bekanntes Beispiel. Wem das erklärt...